Simon Pacey

6.5k total citations · 1 hit paper
69 papers, 3.9k citations indexed

About

Simon Pacey is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Simon Pacey has authored 69 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 32 papers in Oncology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Simon Pacey's work include Prostate Cancer Treatment and Research (12 papers), Heat shock proteins research (11 papers) and Cancer Genomics and Diagnostics (7 papers). Simon Pacey is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Heat shock proteins research (11 papers) and Cancer Genomics and Diagnostics (7 papers). Simon Pacey collaborates with scholars based in United Kingdom, United States and France. Simon Pacey's co-authors include Javier García-Corbacho, Richard D. Baird, Nitzan Rosenfeld, Florent Moulière, Carlos Caldas, Jonathan C. M. Wan, Charles Massie, James D. Brenton, David Gilligan and Chee-Seng Tan and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Simon Pacey

66 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liquid biopsies come of age: towards implementation of circulating tumour DNA

2017 1.8k citations Javier García-Corbacho, Florent Moulière et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Pacey United Kingdom	20	2.2k	1.7k	1.3k	1.1k	448	69	3.9k
Boe Sandahl Sørensen Denmark	37	2.7k 1.2×	1.6k 0.9×	2.0k 1.6×	1.3k 1.2×	290 0.6×	171	4.9k
Luca Roz Italy	33	2.6k 1.2×	2.1k 1.2×	1.8k 1.4×	1.1k 1.0×	384 0.9×	76	4.6k
Hartmut Juhl United States	26	2.1k 1.0×	2.0k 1.1×	1.2k 0.9×	623 0.6×	545 1.2×	65	3.8k
Maguy Del Rio France	27	2.0k 0.9×	1.7k 1.0×	1.8k 1.4×	717 0.7×	874 2.0×	56	3.8k
Richard D. Baird United Kingdom	22	1.7k 0.8×	1.7k 1.0×	1.4k 1.1×	1.0k 0.9×	526 1.2×	87	3.5k
Jesse S. Boehm United States	30	2.9k 1.3×	1.5k 0.8×	1.2k 0.9×	949 0.9×	227 0.5×	51	4.3k
Edward Gabrielson United States	31	1.6k 0.7×	1.0k 0.6×	1.0k 0.8×	965 0.9×	256 0.6×	59	3.4k
Ibiayi Dagogo‐Jack United States	24	2.0k 0.9×	1.3k 0.8×	2.0k 1.6×	1.9k 1.7×	404 0.9×	85	4.5k
Charles Massie United Kingdom	24	2.2k 1.0×	2.1k 1.2×	1.1k 0.8×	1.3k 1.2×	435 1.0×	42	4.0k
Bruno Robert France	32	1.4k 0.6×	1.3k 0.8×	1.4k 1.1×	552 0.5×	507 1.1×	78	3.3k

Countries citing papers authored by Simon Pacey

Since Specialization

Citations

This map shows the geographic impact of Simon Pacey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Pacey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Pacey more than expected).

Fields of papers citing papers by Simon Pacey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Pacey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Pacey. The network helps show where Simon Pacey may publish in the future.

Co-authorship network of co-authors of Simon Pacey

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Pacey. A scholar is included among the top collaborators of Simon Pacey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Pacey. Simon Pacey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pacey, Simon, et al.. (2023). Antibody-Drug Conjugates in Prostate Cancer: A Systematic Review. Cureus. 15(2). e34490–e34490. 14 indexed citations

Crabb, Simon J., Ruth Plummer, Alastair Greystoke, et al.. (2021). 560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations. Annals of Oncology. 32. S617–S617. 6 indexed citations

Hudecova, Irena, Christopher G. Smith, Robert Hänsel‐Hertsch, et al.. (2021). Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. Genome Research. 32(2). 215–227. 58 indexed citations

Zauderer, Marjorie G., Joshua Brody, Thomas U. Marron, et al.. (2019). P2.06-07 Phase 1 Study of CA-170: First-in-Class Small Molecule Targeting VISTA/PD-L1 in Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 14(10). S757–S758. 7 indexed citations

Cassidy, Liam D., Andrew Young, Pedro A. Pérez–Mancera, et al.. (2018). A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo. Autophagy. 14(7). 1256–1266. 28 indexed citations

Jayaram, Anuradha, Karolina Nowakowska, Joaquı́n Mateo, et al.. (2017). Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status. Annals of Oncology. 28. vii30–vii30. 3 indexed citations

Pacey, Simon, Fiona Blackhall, Javier García-Corbacho, et al.. (2016). A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors. Annals of Oncology. 27. vi437–vi437. 1 indexed citations

Tan, Chee-Seng, David Gilligan, & Simon Pacey. (2015). Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. The Lancet Oncology. 16(9). e447–e459. 315 indexed citations

Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations

10.

Pacey, Simon, Richard H. Wilson, Mike Walton, et al.. (2011). A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clinical Cancer Research. 17(6). 1561–1570. 154 indexed citations

11.

Pacey, Simon, Martin Gore, David Chao, et al.. (2010). A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investigational New Drugs. 30(1). 341–349. 103 indexed citations

12.

Gaspar, Nathalie, Swee Y. Sharp, Simon Pacey, et al.. (2009). Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells. Cancer Research. 69(5). 1966–1975. 92 indexed citations

13.

Pacey, Simon, Mark J. Ratain, Keith T. Flaherty, et al.. (2009). Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Investigational New Drugs. 29(3). 481–488. 40 indexed citations

14.

Gaspar, Nathalie, Swee Y. Sharp, Simon Pacey, et al.. (2008). Acquired resistance to HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines. Cancer Research. 68. 2461–2461. 1 indexed citations

15.

Plummer, Ruth, Gerhardt Attard, Simon Pacey, et al.. (2007). Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research. 13(20). 6187–6194. 198 indexed citations

16.

Pacey, Simon, Richard H. Wilson, Mike Walton, et al.. (2007). A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors. Molecular Cancer Therapeutics. 6. 2 indexed citations

17.

Greystoke, Alastair, Sarah P. Blagden, Anne Thomas, et al.. (2006). A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Annals of Oncology. 17(8). 1313–1319. 19 indexed citations

18.

Asad, Yasmin J., et al.. (2006). Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17‐DMAG in human plasma. Rapid Communications in Mass Spectrometry. 20(19). 2845–2850. 8 indexed citations

19.

Pacey, Simon, et al.. (2005). Hsp90 Inhibitors in the Clinic. Handbook of experimental pharmacology. 331–358. 76 indexed citations

20.

McQuaker, I. Grant, et al.. (1997). Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.. Journal of Clinical Oncology. 15(2). 451–457. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact